[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-severe-hypertension\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-severe-hypertension":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100632259","phase-2-study-of-efficacy-and-safety-of-tonlamarsen-in-participants-with-a-recent-hospitalization-and-a-concurrent-episode-of-acute-severe-hypertension-100632259",false,"NCT07511361","Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension","A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Two-Part Study to Evaluate the Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension","KARDINAL-ASH","Key Inclusion Criteria:\n\n* Age 18 or older, body weight ≥ 50 kg with BMI ≤45.0 kg\u002Fm2\n* Ready for discharge or recently discharged from the hospital to home (within the past 7 days) during which evaluation and\u002For treatment of acute severe hypertension (documented SBP ≥ 180 mmHg and\u002For DBP ≥ 110 mmHg) occurred, as measured by a healthcare provider (HCP) within the 24 hours preceding hospitalization or during the initial 24 hours of hospitalization\n* At Screening and Randomization visit, average resting office systolic blood pressure ≥ 145 mmHg\n* Presence of established cardiovascular or renal disease\n\nKey Exclusion Criteria:\n\n* Has known history of secondary hypertension\n* Any malignancy requiring treatment within 5 years (except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated)\n* Has abnormal thyroid function with clinical significance\n* Recent hospitalization for stroke, myocardial infarction or coronary revascularization within 30 days prior to screening\n* History of and\u002For obvious clinical signs or symptoms of cirrhosis or other significant liver disease\n* Alanine aminotransferase or aspartate aminotransferase \\>2 x upper limit of normal\n* Most recent hospitalization was for non-cardiovascular or non-renal conditions","ALL","18 Years",{"count":20,"type":21},140,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The purpose of this study is to evaluate the blood pressure-lowering effect of tonlamarsen in adult participants who were recently hospitalized and concurrently experienced an episode of acute severe hypertension.",[27,28,29,30],"Hypertension","Acute Severe Hypertension","Hypertensive Emergency","Hypertensive Urgency","RECRUITING","2026-06-29",{"date":34,"type":35},"2026-07-01","ACTUAL",{"date":37,"type":35},"2026-06-23",{"date":39,"type":21},"2027-02",{"name":41,"class":42},"Kardigan, Inc.","INDUSTRY",8]